Table 4.
Clinical correlations with altered GMVs and diffusion characteristics of patients with MWoA.
| Disease duration (years) | Duration (hours) | Frequency (times/ months) | Pain intensity VAS | MIDAS | HIT-6 | |
|---|---|---|---|---|---|---|
| Decreased GMVs at SpV | ||||||
| r | 0.119 | 0.169 | -0.249 | 0.044 | -0.221 | 0.038 |
| P value | 0.432 | 0.261 | 0.096 | 0.773 | 0.140 | 0.800 |
| Decreased FA at Vermis VI extending to the bilateral lobule V and bilateral lobule VI | ||||||
| r | -0.047 | -0.250 | 0.347 | 0.006 | 0.190 | 0.110 |
| P value | 0.759 | 0.094 | 0.018 | 0.970 | 0.206 | 0.465 |
| Increased AD at R-ICP | ||||||
| r | -0.058 | -0.125 | 0.160 | 0.218 | 0.106 | 0.120 |
| P value | 0.703 | 0.407 | 0.289 | 0.146 | 0.485 | 0.425 |
| increased MD at R-ICP | ||||||
| r | -0.105 | -0.072 | 0.139 | 0.147 | 0.064 | 0.050 |
| P value | 0.486 | 0.633 | 0.355 | 0.330 | 0.671 | 0.741 |
| increased RD at R-ICP | ||||||
| r | -0.155 | -0.051 | 0.123 | 0.114 | 0.065 | 0.033 |
| P value | 0.305 | 0.734 | 0.416 | 0.449 | 0.670 | 0.827 |
| increased AD at SpV | ||||||
| r | -0.246 | 0.034 | 0.107 | -0.023 | -0.050 | -0.135 |
| P value | 0.099 | 0.823 | 0.479 | 0.881 | 0.740 | 0.370 |
| increased MD at SpV | ||||||
| r | -0.234 | 0.053 | 0.105 | -0.036 | -0.038 | -0.165 |
| P value | 0.118 | 0.728 | 0.486 | 0.814 | 0.803 | 0.273 |
| increased RD at SpV | ||||||
| r | -0.250 | 0.087 | 0.106 | -0.044 | -0.041 | -0.162 |
| P value | 0.094 | 0.566 | 0.482 | 0.770 | 0.786 | 0.283 |
VAS Visual analogue scale, MIDAS Migraine disability assessment scale, HIT-6 Headache impact test; Frequency: the average number of attacks per month in the last three month; AD Axial diffusivity, MD Mean diffusivity, RD Radial diffusivity, FA Fractional anisotropy, SCP Superior cerebellar peduncle, MCP Middle cerebellar peduncle, ICP Inferior cerebellar peduncle, SpV Spinal trigeminal nucleus, r Spearson’s rho; Significant correlations were determined according to p<0.0083 (Bonferroni corrected for multiple comparisons, p<0.05).